Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Ann Clin Transl Neurol · 2026 · PMC13394542 · PMID 41968564

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the increased risk of CDW and PIRA did not reach statistical significance, a significantly higher hazard was identified for PIRMA in the rituximab arm.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.